Debbie Rigby rounds up the latest in research news
There is strong evidence that both BNZ and Z-drugs are associated with an increased risk of hip fracture in the older person, and there is little difference between their respective risks. Patients newly prescribed these medicines are at the greatest risk of hip fracture.
PLoS ONE 12(4):e0174730.
This guideline recommends deprescribing PPIs (reducing dose, stopping, or using “on-demand” dosing) in adults who have completed a minimum of 4 weeks of PPI treatment for heartburn or mild to moderate gastroesophageal reflux disease or esophagitis, and whose symptoms are resolved.
Canadian Family Physician 2017;63(5):354-364.
A systematic review has found that all NSAIDs, including naproxen, are associated with an increased risk of acute myocardial infarction. Risk of myocardial infarction with celecoxib is comparable to that of traditional NSAIDS and was lower than for rofecoxib. Risk was greatest during the first month of NSAID use and with higher doses.
A systematic review and meta-analysis has shown that LABA/LAMA combinations demonstrate a better effiacy and saefty profile than LAMA or LABA/ICS. LABA/LAMA significantly improve lung function compared to both LAMA and LABA/ICS. LABA/LAMA significantly improve dyspnoea and quality of life comapred to LAMAs but not ICS/LAMAs, and significantly reduce moderate/severe exacerbation rate compared with LABA/ICS. Adverse event incidence was no different for LABA/LAMA versus LAMA treatment, but it was lower versus LABA/ICS.
International Journal of COPD 2017:12 907–922.